Table 1.

Relative viability of melanoma lymph node metastases analyzed ex vivo after treatment with Vemurafenib and/or Cobimetinib

Patient No.	Mutation	Relative viability (% of control) 1
		Vemurafenib	Cobimetinib	Vemurafenib/Cobimetinib
		(2 μM)	(50 nM)	(2 μM + 50 nM)
Melmet-339	BRAF	34	38	n.a.*
Melmet-347	BRAF	31	29	n.a.
Melmet-363	BRAF	52	39	n.a.
Melmet-368	BRAF	64	52	n.a.
Melmet-376	BRAF	52	40	n.a.
Melmet-380	BRAF	16	16	14
Melmet-381	BRAF	26	10	16
Melmet-382	BRAF	30	35	29
Melmet-396	BRAF	24	17	20
Melmet-397	BRAF	36	32	48
Melmet-352	NRAS	81	78	n.a.
Melmet-360	NRAS	127	55	n.a.
Melmet-367	NRAS	91	117	n.a.
Melmet-369	NRAS	74	40	n.a.
Melmet-388	NRAS	89	48	83
Melmet-399	NRAS	86	49	55
Melmet-432	NRAS	108	42	73
Melmet-370	Wt/Wt	70	92	n.a.

¹ Percentage survival.

* n.a. = Not analyzed.